<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01067326</url>
  </required_header>
  <id_info>
    <org_study_id>09-007617</org_study_id>
    <secondary_id>R01AG031750</secondary_id>
    <secondary_id>R01HL092954</secondary_id>
    <nct_id>NCT01067326</nct_id>
  </id_info>
  <brief_title>The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis</brief_title>
  <official_title>The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Aging (NIA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will study the hypothesis that long-term Tekturna treatment will improve endothelial
      function and the production and function of endothelial progenitor cells (EPCs) in patients
      with early atherosclerosis. Specifically, long-term Tekturna treatment will increase the
      Reactive Hyperemia Peripheral Arterial Tonometry indexes and increase the numbers and the
      function of circulating endothelial progenitor cells, compared to placebo, in association
      with a reduction in inflammation and oxidative stress.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aliskiren is a direct renin-inhibitor and may have beneficial effects on the vascular
      endothelium, similar to other antihypertensive therapies targeting the
      renin-angiotensin-aldosterone system (RAAS). The current study was designed to test the
      hypothesis that aliskiren improves endothelial function and increases the number of
      endothelial progenitor cells (EPCs) in normotensive patients with early atherosclerosis.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Novartis ended all studies regarding Aliskiren.
  </why_stopped>
  <start_date>February 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Endothelial Progenitor Cells (EPC)</measure>
    <time_frame>Baseline, 4 Months</time_frame>
    <description>Peripheral blood mononuclear cells were stained for EPC markers (cell-surface antigens CD34/CD133/KDR) and counted by flow-cytometry.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reactive Hyperemia Index (RHI)</measure>
    <time_frame>Baseline, 4 Months</time_frame>
    <description>RHI was measured by the noninvasive endothelial peripheral arterial tomography (EndoPat) test. EndoPAT results are reported as the &quot;Endoscore&quot; (range 0-3); a score of 1.67 and lower indicates the need for immediate medical attention; a score between 1.68 and 2 indicates a need to reduce risk factors; a score above 2.1 indicates a healthy heart.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure</measure>
    <time_frame>Baseline, 4 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure</measure>
    <time_frame>Baseline, 4 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Aliskiren</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 mg Aliskiren once daily for a period of 4 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 pill per day by mouth for 4 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aliskiren</intervention_name>
    <description>150 mg Aliskiren once daily for a period of 4 months</description>
    <arm_group_label>Aliskiren</arm_group_label>
    <other_name>Tekturna</other_name>
    <other_name>Rasilez</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 pill per day by mouth for 4 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years old

          2. More than two of the following cardiovascular risk factors (determined by prescreen
             phone call): family history of cardiovascular disease, physical inactivity/sedentary
             lifestyle, obesity or overweight, family history of diabetes mellitus or hypertension,
             total cholesterol &gt; 200 mg/dL, LDL &gt; 130 mg/dL, HDL &lt; 50 mg/dL, smoking, stress, or
             Triglycerides &gt; 150 mg/dL

          3. Demonstrated endothelial dysfunction (reactive hyperemia - EndoPAT score &lt; 2.0) at
             time of screening

        Exclusion Criteria:

          1. Serum potassium &gt; 5.0 mmol/L documented at any time prior to the study

          2. History of any cardiovascular event (stroke, transient ischemic attack (TIA),
             myocardial infarction (MI), unstable angina, coronary artery bypass grafting (CABG),
             percutaneous coronary intervention, hospitalization due to heart failure) during the 3
             months prior to the study

          3. Hypertension or hypotension (at Randomization): any patient with Mean Seated Systolic
             Blood Pressure (msSBP) ≥ 170 mmHg, msSBP &lt; 100 mmHg or Mean Seated Diastolic Blood
             Pressure (msDBP) ≥ 110 mmHg

          4. Congestive heart failure New York Heart Association (NYHA) class III and IV

          5. Concomitant treatment with two (2) or more renin-angiotensin-aldosterone system
             blocking agents, e.g. Angiotensin Converting Enzyme Inhibitor (ACEI), Angiotensin II
             receptor blockers (ARB) or aldosterone-antagonist

          6. Unstable serum creatinine

          7. Second (II) or third (III) degree heart block without a pacemaker

          8. Concurrent potentially life threatening arrhythmia or other uncontrolled arrhythmia

          9. Clinically significant valvular heart disease

         10. Known renal artery stenosis

         11. Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism, or excretion of the study drugs including, but not limited
             to, any of the following:

               -  History of major gastrointestinal tract surgery such as gastrectomy,
                  gastroenterostomy, or bowel resection

               -  Any history of pancreatic injury, pancreatitis or evidence of impaired pancreatic
                  function/injury as indicated by abnormal lipase or amylase

               -  Evidence of hepatic disease as determined by a history of hepatic encephalopathy,
                  a history of cirrhosis, esophageal varices, or a history of portocaval shunt

         12. History of malignancy other than basal cell skin cancer within the past five years

         13. Any concurrent life threatening condition with a life expectancy less than 2 years

         14. History or evidence of drug or alcohol abuse within the last 12 months

         15. Any surgical or medical condition, which in the opinion of the investigator, may place
             the patient at higher risk from his/her participation in the study, or is likely to
             prevent the patient from complying with the requirements of the study or completing
             the study

         16. History of hypersensitivity to any of the study drugs or to medications belonging to
             the same therapeutic class as the study drugs as well as known or suspected
             contraindications to the study drugs

         17. History of noncompliance to medical regimens or unwillingness to comply with the study
             protocol

         18. Use of other investigational drugs at the time of enrollment, or within 30 days or 5
             half-lives of enrollment, whichever is longer

         19. Any condition that in the opinion of the investigator would jeopardize the evaluation
             of efficacy or safety

         20. Persons directly involved in the execution of this protocol

         21. Pregnant or nursing (lactating) women

         22. Women of Child-Bearing Potential (WOCBP) unless postmenopausal for at least one year,
             surgically sterile or using effective methods of contraception as defined by local
             Health Authorities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amir Lerman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2010</study_first_submitted>
  <study_first_submitted_qc>February 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2010</study_first_posted>
  <results_first_submitted>January 9, 2013</results_first_submitted>
  <results_first_submitted_qc>January 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 13, 2013</results_first_posted>
  <last_update_submitted>January 9, 2013</last_update_submitted>
  <last_update_submitted_qc>January 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 13, 2013</last_update_posted>
  <responsible_party>
    <name_title>Amir Lerman, MD</name_title>
    <organization>Mayo Clinic</organization>
  </responsible_party>
  <keyword>Endothelial Dysfunction</keyword>
  <keyword>Endothelial Function</keyword>
  <keyword>Tekturna</keyword>
  <keyword>Endothelial Peripheral Arterial Tomography (EndoPAT)</keyword>
  <keyword>Progenitor Cells</keyword>
  <keyword>renin inhibition</keyword>
  <keyword>endothelial progenitor cells</keyword>
  <keyword>early atherosclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the Division of Cardiology at the Mayo Clinic in Rochester, Minnesota. 22 subjects were randomized to the study, 2 subjects were affected by the early study termination and thus have no follow-up data.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Aliskiren</title>
          <description>150 mg Aliskiren once daily for a period of 4 months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>1 pill per day by mouth for 4 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Early Study Termination</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Aliskiren</title>
          <description>150 mg Aliskiren once daily for a period of 4 months. Not all baseline data were available from &quot;started&quot; subjects, therefore only baseline data for &quot;completed&quot; subjects is presented.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>1 pill per day by mouth for 4 months. Not all baseline data were available from &quot;started&quot; subjects, therefore only baseline data for &quot;completed&quot; subjects is presented.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Not all baseline data were available from &quot;started&quot; subjects, therefore only baseline data for &quot;completed&quot; subjects is presented.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.1" spread="17.5"/>
                    <measurement group_id="B2" value="51.0" spread="20.7"/>
                    <measurement group_id="B3" value="45.4" spread="18.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <description>Not all baseline data were available from &quot;started&quot; subjects, therefore baseline data for &quot;completed&quot; subjects is presented.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Not all baseline data were available from &quot;started&quot; subjects, therefore baseline data for &quot;completed&quot; subjects is presented.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Endothelial Progenitor Cells (EPC)</title>
        <description>Peripheral blood mononuclear cells were stained for EPC markers (cell-surface antigens CD34/CD133/KDR) and counted by flow-cytometry.</description>
        <time_frame>Baseline, 4 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>150 mg Aliskiren once daily for a period of 4 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 pill per day by mouth for 4 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Progenitor Cells (EPC)</title>
          <description>Peripheral blood mononuclear cells were stained for EPC markers (cell-surface antigens CD34/CD133/KDR) and counted by flow-cytometry.</description>
          <units>counts per 100,000 gated events</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24" lower_limit="1" upper_limit="35"/>
                    <measurement group_id="O2" value="9" lower_limit="3" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="15"/>
                    <measurement group_id="O2" value="8" lower_limit="2" upper_limit="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Change in EPCs from baseline to 4 months</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure</title>
        <time_frame>Baseline, 4 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>150 mg Aliskiren once daily for a period of 4 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 pill per day by mouth for 4 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124.6" spread="12.2"/>
                    <measurement group_id="O2" value="118.8" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112.3" spread="12.4"/>
                    <measurement group_id="O2" value="116.2" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Difference in systolic blood pressure from baseline to 4 months.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>.006</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure</title>
        <time_frame>Baseline, 4 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>150 mg Aliskiren once daily for a period of 4 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 pill per day by mouth for 4 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8" spread="9.9"/>
                    <measurement group_id="O2" value="68.6" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" spread="11.6"/>
                    <measurement group_id="O2" value="67.6" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Difference in diastolic blood pressure from baseline to 4 months.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.04</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Reactive Hyperemia Index (RHI)</title>
        <description>RHI was measured by the noninvasive endothelial peripheral arterial tomography (EndoPat) test. EndoPAT results are reported as the &quot;Endoscore&quot; (range 0-3); a score of 1.67 and lower indicates the need for immediate medical attention; a score between 1.68 and 2 indicates a need to reduce risk factors; a score above 2.1 indicates a healthy heart.</description>
        <time_frame>Baseline, 4 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Aliskiren</title>
            <description>150 mg Aliskiren once daily for a period of 4 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>1 pill per day by mouth for 4 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Reactive Hyperemia Index (RHI)</title>
          <description>RHI was measured by the noninvasive endothelial peripheral arterial tomography (EndoPat) test. EndoPAT results are reported as the &quot;Endoscore&quot; (range 0-3); a score of 1.67 and lower indicates the need for immediate medical attention; a score between 1.68 and 2 indicates a need to reduce risk factors; a score above 2.1 indicates a healthy heart.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" lower_limit="1.66" upper_limit="1.99"/>
                    <measurement group_id="O2" value="1.81" lower_limit="1.63" upper_limit="2.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.73" lower_limit="1.56" upper_limit="2.01"/>
                    <measurement group_id="O2" value="1.68" lower_limit="1.41" upper_limit="2.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P-value for intergroup comparison of change from baseline to month 4</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.94</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>A study coordinator contacted the subjects by phone once weekly for the first month of the study and every month thereafter for the remainder of the study (4 months) to insure the safety of the subjects.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Aliskiren</title>
          <description>150 mg Aliskiren once daily for a period of 4 months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>1 pill per day by mouth for 4 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Irritated bowel</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated early due to safety concerns from the ALTITUDE trial; there was an unexpected increase in adverse events (non-fatal stroke, renal complications, hyperkalemia and hypotension). Novartis ended all studies regarding Aliskiren.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Amir Lerman</name_or_title>
      <organization>Mayo Clinic</organization>
      <phone>507-255-4152</phone>
      <email>lerman.amir@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

